NCT07906418Not yet recruiting
BCMA Polymorphisms in Patients With Multiple Myeloma
The Effect of B Cell Maturation Antigen (BCMA) Polymorphisms on Treatment Response and Survival in Patients With Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The aim of this study is to investigate the effect of B cell maturation antigen (BCMA, TNFRSF17) gene polymorphisms on treatment response and survival in patients with multiple myeloma. BCMA is a member of the tumor necrosis factor receptor superfamily that is expressed on late memory B cells and all plasma cells. Together with the B cell activating factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), BCMA binds the ligands B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby regulating the survival, maturation, and differentiation of B cells and plasma cells. In this study, BCMA polymorphisms will be analyzed by next-generation sequencing in stored genomic DNA samples from 320 patients with multiple myeloma and 100 healthy controls. Genotype frequencies will be compared between patients and controls, and their association with response to first-line treatment, progression-free survival, and overall survival will be evaluated in patients with multiple myeloma.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 420 (estimated)
- First submitted
- 15 Oct 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Başakşehir Çam & Sakura City Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07906418
What you commit to
- Study type: Observational
- Planned participants: 420
- From 1 Nov 2026 to the primary completion date, 15 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, solitary plasmacytoma, plasma cell leukemia, POEMS syndrome, or primary AL amyloidosis without multiple myeloma
- History of another malignancy, except adequately treated non-melanoma skin cancer or carcinoma in situ
Other
- Insufficient or degraded DNA sample, or failed sequencing quality control
- First-degree relationship with another participant already included in the study
Who the study is looking for
- Patients with multiple myeloma:
- Age 18 years or older at diagnosis
- Diagnosed symptomatic multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
- Completion of four cycles of first-line induction therapy
- Availability of a stored genomic DNA sample of sufficient quantity and quality for next-generation sequencing
- Availability of baseline clinical data (Durie-Salmon stage, ISS stage, ECOG performance status, laboratory data) and treatment response and survival data
- Written informed consent for the use of biological samples and clinical data for genetic research
- Healthy controls:
- Age 18 years or older
- No known hematological disease, malignancy, or chronic inflammatory or autoimmune disease
- Availability of a stored genomic DNA sample of sufficient quantity and quality for next-generation sequencing
- Written informed consent for the use of biological samples for genetic research
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul Basaksehir Cam and Sakura City Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.